Sickle cell patient's journey leads to landmark approval of gene-editing treatment
Four years ago, Victoria Gray was lying in a hospital bed, exhausted by a lifetime with sickle cell disease and recovering from a grueling experimental treatment she hoped would save her.
Today, the Forest, Miss., mother of four is brimming with energy and hope. She's working full time, keeping up with her teenage children and traveling the world with her husband.
Gray's transformation is the result of the landmark medical experiment that she launched and which culminated in December with a milestone: The Food and Drug Administration's approved the first treatment that uses gene-editing to alleviate a human illness. It's the first genetic therapy for the brutal blood disorder, which had long been neglected by medicine.
For the past and had exclusive access to report on her ensuing experience.
You’re reading a preview, subscribe to read more.
Start your free 30 days